Our Outlook for the Health-Care Sector
The pendulum may have swung too far at the FDA.
Fortunately, health-care companies are generally not subject to the cyclical vagaries of rising interest rates or tightening credit conditions. People still get sick as they get older, whether the macroeconomic picture is looking up or trending down. However, a whole swath of companies in the health-care sector--including biotech, branded and generic pharmaceutical, and device manufacturers--do have to contend with the Food and Drug Administration, which oversees manufacturing facilities, product safety and approvals, marketing practices, and post-approval quality measures.
Debbie Wang has a position in the following securities mentioned above: PFE, VTRS. Find out about Morningstar’s editorial policies.